Evidence map›Paper›PMID 21816416›Full record

ArticleThe Journal of surgical research2011

Enhancing complement control on endothelial barrier reduces renal post-ischemia dysfunction.

Sathnur B Pushpakumar, Gustavo Perez-Abadia, Chirag Soni, Rong Wan, Nathan Todnem, Phani K Patibandla, Tathyana Fensterer, Qunwei Zhang, John H Barker, Claudio Maldonado

Open access · greenAbstract read
In one paragraph

Article in The Journal of surgical research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Innate immunity in donor procurement.Current opinion in organ transplantation · 2013
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Sathnur B PushpakumarDepartment of Physiology and Biophysics, University of Louisville, Louisville, Kentucky, USA.
Gustavo Perez-Abadia
Chirag Soni
Rong Wan
Nathan Todnem
Phani K Patibandla
Tathyana Fensterer
Qunwei Zhang
John H Barker
Claudio Maldonado
University of Louisville · US

Funding

New anti-complement therapy to reduce reperfusion injury: Phase IIR42HL079855 · NHLBI · ENDOPROTECH, INC. · PI MALDONADO, CLAUDIO · 2008 to 2009
$964k
New anti-complement therapy to reduce reperfusion injuryR41HL079855 · NHLBI · ENDOPROTECH, INC. · PI MALDONADO, CLAUDIO · 2005 to 2005
$123k
NHLBI NIH HHS R41 HL079855NHLBI NIH HHS R41HL079855NHLBI NIH HHS R42 HL079855
6 · The paper itself

Abstract

backgroundExcessive complement activation is an integral part of ischemia and reperfusion (IR) injury (IRI) of organs. In kidney transplantation, the pathologic consequence of IRI and complement activation can lead to delayed graft function, which in turn is associated with acute rejection. Previous strategies to reduce complement-induced IRI required systemic administration of agents, which can lead to increased susceptibility to infections/immune diseases. The objective of this study was to determine whether an increase in complement control defenses of rat kidney endothelium reduces IRI. We hypothesized that increased complement control on the endothelial barrier reduces IR-mediated complement activation and reduces kidney dysfunction. MATERIALS AND

methodsFischer 344 rats underwent left kidney ischemia for 45 min and treatment with a novel fusogenic lipid vesicle (FLVs) delivery system to decorate endothelial cells with vaccinia virus complement control protein (VCP), followed by reperfusion for 24 h. Assessment included renal function by serum creatinine and urea, myeloperoxidase assay for neutrophil infiltration, histopathology, and quantification of C3 production in kidneys.

resultsAnimals in which the kidney endothelium was bolstered by FLVs+VCP treatment had better renal function with a significant reduction in serum creatinine compared with vehicle controls (P < 0.05). Also, C3 production was significantly reduced (P < 0.05) in treated animals compared with vehicle controls.

conclusionIncreasing complement control at the endothelial barrier with FLVs+VCP modulates complement activation/production during the first 24 h, reducing renal dysfunction following IRI.

Indexed as

Kidney DiseasesReperfusion InjuryAnimalsComplement ActivationComplement C3CreatinineEndothelial CellsKidney Function TestsLiposomesMaleNeutrophilsPermeabilityPeroxidaseRatsRats, Inbred F344UreaComplement C3complement-control protein, Vaccinia virusCreatinineLiposomesPeroxidaseUreaViral Proteins

Identifiers

PMID21816416
PMCPMC3175310
OpenAlexW2105805676

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.